- Previous Close
68.82 - Open
68.68 - Bid 41.98 x --
- Ask 33.20 x --
- Day's Range
68.82 - 68.82 - 52 Week Range
32.72 - 68.82 - Volume
290 - Avg. Volume
8 - Market Cap (intraday)
1.403B - Beta (5Y Monthly) 0.04
- PE Ratio (TTM)
1,720.62 - EPS (TTM)
0.04 - Earnings Date Feb 26, 2025 - Mar 3, 2025
- Forward Dividend & Yield 0.65 (0.94%)
- Ex-Dividend Date Jun 12, 2024
- 1y Target Est
--
Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Italy, Germany, Ireland, France, rest of the European Union, the United States, and internationally. The company operates through Oncology and RNA Interference segments. It develops and commercializes Yondelis for the treatment of soft tissue sarcoma and for ovarian cancer; Aplidin for treating R/R multiple myeloma; and Zepzelca to treat patients with small cell lung cancer. The company develops Ecubectedin (PM14), which is in phase II clinical trials for the treatment of solid tumors, as well as in Phase I clinical trials for the treatment of soft tissue sarcoma and prostate cancer; PM534 that is Phase I clinical trials for treating solid tumors; PM54, which is in Phase I clinical trials for the treatment of solid tumors; SYL1801 that is in phase II clinical trials for treating macular degeneration; SYL116011, which is in preclinical studies for the treatment of ocular allergies; and SYL A and B that is in investigational studies to treat retinitis pigmentosa. In addition, it engages in the research, development, production, and sale of products with therapeutic activity based on reducing or silencing gene expression. Pharma Mar, S.A. was incorporated in 1986 and is based in Madrid, Spain.
www.pharmamar.comRecent News: PHME.XC
View MorePerformance Overview: PHME.XC
Trailing total returns as of 12/20/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PHME.XC
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PHME.XC
View MoreValuation Measures
Market Cap
1.36B
Enterprise Value
1.26B
Trailing P/E
1.67k
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
7.16
Price/Book (mrq)
6.56
Enterprise Value/Revenue
7.53
Enterprise Value/EBITDA
235.45
Financial Highlights
Profitability and Income Statement
Profit Margin
0.37%
Return on Assets (ttm)
-0.65%
Return on Equity (ttm)
0.32%
Revenue (ttm)
167M
Net Income Avi to Common (ttm)
622k
Diluted EPS (ttm)
0.04
Balance Sheet and Cash Flow
Total Cash (mrq)
144.39M
Total Debt/Equity (mrq)
29.35%
Levered Free Cash Flow (ttm)
-17.05M